📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. (2021)

First Author: Kennedy NA

Attributed to: Regulatory T cell therapy for IBD funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/gutjnl-2021-324789

PubMed Identifier: 33903149

Publication URI: http://europepmc.org/abstract/MED/33903149

Type: Journal Article/Review

Volume: 70

Parent Publication: Gut

Issue: 10

ISSN: 0017-5749